Literature DB >> 12642839

Long-term assessment of T-cell populations in DiGeorge syndrome.

Javier Chinen1, Howard M Rosenblatt, E O'Brian Smith, William T Shearer, Lenora M Noroski.   

Abstract

BACKGROUND: Patients with DiGeorge syndrome present with a broad range of T-cell deficiency. Partial DiGeorge syndrome (pDGS) is a preferred designation for patients with detectable T-cell function. Among immunology experts, there is no uniform opinion on the necessity of T-cell precautions for pDGS patients. Few studies have addressed the natural course of their immune function over time.
OBJECTIVE: The objective of this study was to describe the natural history of immune parameters in pDGS.
METHODS: We reviewed the medical records of 45 pDGS patients. Peripheral blood T-cell subsets counts and percentages were recorded at 1, 6, 12, 18, 24, 30, 48, 60, 72, 96, and 120 months of age, and the rates of change of T-cell measurements over the follow-up period (slopes) were calculated for each individual. Humoral immunity was evaluated by quantification of immunoglobulins and by testing antibody titers to recall antigens.
RESULTS: T-cell subsets counts from pDGS patients were generally lower than those of age-matched normal populations but were not severely depressed (ie, CD4+ T-cell percentage less than 15%). The median of the slopes for CD3+, CD4+, and CD8+ T-cell percentages were -0.7%, -0.8%, and -0.1%/month, respectively, in the first year of age and 0.1%/month for each subpopulation from 12 to 120 months of age. Lymphoproliferative responses to phytohemagglutinin were adequate at all ages. Immunoglobulin deficiencies or inadequate production of specific antibodies were not detected.
CONCLUSIONS: In our pDGS patient cohort, a significant deterioration of T-cell number or function did not occur over time. Clinical implications of this finding include the possibility of discontinuing T-cell deficiency precautions and frequency of reevaluations of pDGS patients with stable and adequate immune function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642839     DOI: 10.1067/mai.2003.165

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  23 in total

1.  Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  R Zemble; E Luning Prak; K McDonald; D McDonald-McGinn; E Zackai; K Sullivan
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

2.  Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.

Authors:  Yiwa Suksawat; Achara Sathienkijkanchai; Jittima Veskitkul; Orathai Jirapongsananuruk; Nualanong Visitsunthorn; Pakit Vichyanond; Punchama Pacharn
Journal:  J Clin Immunol       Date:  2017-04-20       Impact factor: 8.317

Review 3.  Thymus transplantation.

Authors:  M Louise Markert; Blythe H Devlin; Elizabeth A McCarthy
Journal:  Clin Immunol       Date:  2010-03-16       Impact factor: 3.969

Review 4.  Application of Flow Cytometry in the Evaluation of Primary Immunodeficiencies.

Authors:  Thomas A Fleisher; Manisha Madkaikar; Sergio D Rosenzweig
Journal:  Indian J Pediatr       Date:  2016-02-11       Impact factor: 1.967

5.  A Case of CATCH22 Syndrome Diagnosed in Postmenopausal Woman.

Authors:  Seung Kyung Lee; Min Jeong Lee; Hyo Jin Lee; Bu Kyung Kim; Young Bae Sohn; Yoon-Sok Chung
Journal:  J Bone Metab       Date:  2013-05-13

6.  Persistent low thymic activity and non-cardiac mortality in children with chromosome 22q11.2 microdeletion and partial DiGeorge syndrome.

Authors:  P Eberle; C Berger; S Junge; S Dougoud; E Valsangiacomo Büchel; M Riegel; A Schinzel; R Seger; T Güngör
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

7.  CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features.

Authors:  Soma Jyonouchi; Donna M McDonald-McGinn; Sherri Bale; Elaine H Zackai; Kathleen E Sullivan
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

Review 8.  22q11.2 deletion syndrome.

Authors:  Donna M McDonald-McGinn; Kathleen E Sullivan; Bruno Marino; Nicole Philip; Ann Swillen; Jacob A S Vorstman; Elaine H Zackai; Beverly S Emanuel; Joris R Vermeesch; Bernice E Morrow; Peter J Scambler; Anne S Bassett
Journal:  Nat Rev Dis Primers       Date:  2015-11-19       Impact factor: 52.329

9.  SAPHO osteomyelitis and sarcoid dermatitis in a patient with DiGeorge syndrome.

Authors:  Harumi Jyonouchi; Kenneth W Lien; Helen Aguila; Gaetano G Spinnato; Sanjeev Sabharwal; Beth A Pletcher
Journal:  Eur J Pediatr       Date:  2006-02-21       Impact factor: 3.183

10.  Maturational alterations of peripheral T cell subsets and cytokine gene expression in 22q11.2 deletion syndrome.

Authors:  Y Kanaya; S Ohga; K Ikeda; K Furuno; T Ohno; H Takada; N Kinukawa; T Hara
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.